BRAF and neoplasm: Our study is population‐based and therefore includes more patients with older age, worse PS, comorbidity and less treatment compared to clinical trials, however, patients without available or sufficient tumor tissue for analysis could not be included and these patients have a particularly poor prognosis.7 Despite this being the largest population‐based study reporting on MSI and BRAF status and its effect on survival in mCRC, the number of patients in some of the MSI/BRAF subgroups was still limited.